Warfarin versus low-molecular-weight heparin therapy in cancer patients

Oncologist

Volumn 10, Issue 1, 2005, Pages 72-79

  Zacharski, Leo R ^a   Prandoni, Paolo ^b   Monreal, Manuel ^c  

^a Department of Veterans Affairs Regional Office White River Junction   (United States)

^b UNIVERSITY OF PADOVA   (Italy)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Cancer; Dalteparin; Low molecular weight heparin; Warfarin

Indexed keywords

DALTEPARIN; FLUOROURACIL; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTICOAGULATION; BLEEDING; CANCER; CANCER INCIDENCE; CANCER RISK; CENTRAL VENOUS CATHETERIZATION; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; HUMAN; INTERNATIONAL NORMALIZED RATIO; LONG TERM CARE; LOW DRUG DOSE; LUNG SMALL CELL CANCER; META ANALYSIS; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; ANTICOAGULANTS; DRUG INTERACTIONS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALNUTRITION; NEOPLASMS; RISK FACTORS; THROMBOEMBOLISM; VOMITING; WARFARIN;

EID: 12844269949     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.10-1-72     Document Type: Review

References (49)

1. Sue-Ling HM, Johnston D, McMahon MU et al. Pre-operative Identification of patients at high risk of deep venous thrombosis after elective major abdominal surgery. Lancet 1986;1:1173-1176.
2. Sproul E. Carcinoma and venous thrombosis: the frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis. Am J Cancer 1938;34:566-585.
3. Lindblad B, Sternby N, Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. BMJ 1991;302:709-711.
4. Lee AY. Cancer and thromboembolic disease: pathogenic mechanisms. Cancer Treat Rev 2002;28:137-140.
5. Shen V, Pollak E. Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified? South Med J 1980;73:841-843.
6. Levitan N, Dowlati A, Remick S et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using medicare claims data. Medicine 1999;78:285-291.
7. Sorensen H, Mellemkjaer L, Olsen J et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846-1850.
8. Zacharski LR. Anticoagulants in cancer treatment: malignancy as a solid-phase coagulopathy. Cancer Lett 2002;186:1-9.
9. Hirsh J, Fuster V, Ansell J et al. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003;107:1692-1711.
10. Levine MN. Managing thromboembolic disease in the cancer patient: efficacy and safety of antithrombotic treatment options in patients with cancer. Cancer Treat Rev 2002;28:145-149.
11. Lee AY. Treatment of venous thromboembolism in cancer patients. Thromb Res 2001;102:V195-V208.
12. Bona RD, Mickey AD, Wallace DM. Warfarin is safe as secondary prophylaxis in patients with cancer and a previous episode of venous thrombosis. Am J Clin Oncol 2000;23:71-73.
13. Hutten BA, Prins MH, Gent M et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000;18:3078-3083.
14. Palareti G, Legnani C, Lee A et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with and without malignancy. Thromb Haemost 2000;84:805-810.
15. Prandoni P, Lensing AWA, Piccioli A et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-3488.
16. Linkins L, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003;139:893-900.
17. Gitter MJ, Jaeger TM, Petterson TM et al. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. Mayo Clin Proc 1995;70:725-733.
18. White RH, Beyth RJ, Zhou H et al. Major bleeding after hospitalization for deep-venous thrombosis. Am J Med 1999;107:414-424.
19. Masci G, Magagnoli M, Zucali PA et al. Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy? J Clin Oncol 2003;21:736-739.
20. Levine MN. Managing thromboembolic disease in the cancer patient: efficacy and safety of antithrombotic treatment options in patients with cancer. Cancer Treat Rev 2002;28:145-149.
21. Zacharski LR, Ornstein DL. Heparin and cancer. Thromb Haemost 1998;80:10-23.
22. Zacharski LR, Ornstein DL, Mamourian AC. Low-molecular-weight heparin and cancer. Semin Thromb Hemost 2000;26(suppl 1):69-77.
23. Zacharski LR, Henderson WG, Rickles FR et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate: final report of VA Cooperative Study #75. Cancer 1984;53:2046-2052.
24. Chahinian AP, Propert KJ, Ware JH et al. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol 1989;7:993-1002.
25. Aisner J, Goutsou M, Maurer LH et al. Intensive combination chemotherapy, concurrent chest irradiation, and warfarin for the treatment of limited-disease small-cell lung cancer: a Cancer and Leukemia Group B pilot study. J Clin Oncol 1992;10:1230-1236.
26. Maurer LH, Herndon JE 2nd, Mollis DR et al. Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. J Clin Oncol 1997;15:3378-3387.
27. Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. N Engl J Med 2000;342:1953-1958.
28. Taliani MR, Agnelli G, Prandoni P et al. Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation. J Thromb Haemost 2003;1:1730-1733.
29. Thodiyil P, Kakkar AK. Can low-molecular-weight heparins improve outcomes in patients with cancer? Cancer Treat Rev 2002;28:151-155.
30. Pini M, Aiello S, Manotti C et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 1994;72:191-197.
31. Das SK, Cohen AT, Edmonson RA et al. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg 1996;20:521-527.
32. Lopaciuk S, Bielska-Falda H, Noszczyk W et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemost 1999;81:26-31.
33. Gonzalez-Fajardo J, Arreba W, Castrodeza J et al. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep vein thrombosis. J Vasc Surg 1999;30:283-292.
34. Veiga F, Escriba A, Maluenda M et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep vein thrombosis in the elderly: a randomized trial. Thromb Haemost 2000;84:559-564.
35. Hull R, Pineo G, Mah AF. Long-term low molecular weight heparin treatment versus oral anticoagulant therapy for proximal deep vein thrombosis. Blood 2000;96:449a.
36. Iorio A, Guercini F, Pini M. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. J Thromb Haemost 2003;1:906-1913.
37. Meyer G, Marjanovic Z, Valcke J et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer. Arch Int Med 2002;162:1729-1735.
38. Hull R, Pineo G, Mah AF et al. A randomised trial evaluating long-term low-molecular-weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Blood 2002;100:148a.
39. Deitcher SR, Kessler CM, Merli G et al. Secondary prevention of venous thromboembolic events (VTE) in patients with active malignancy: a randomised study of enoxaparin sodium alone versus initial enoxaparin sodium followed by warfarin for a 180-day period. Proc Am Soc Clin Oncol 2003;22:761.
40. Bern MM, Lokich JJ, Wallach SR et al. Very low doses of warfarin can prevent thrombosis in central venous catheters: a randomised prospective trial. Ann Intern Med 1990;112:423-428.
41. Monreal M, Alastrue A, Rull M et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices - prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 1996;75:251-253.
42. Mismetti P, Mille D, Laporte S et al. Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial. Haematologica 2003;88:67-73.
43. Lee AY, Levine MN, Baker RI et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New Engl J Med 2003;349:146-153.
44. Lee AYY, Julian A, Levine MN et al. Impact of dalteparin low-molecular-weight heparin (LMWH) on survival: results of a randomized trial in cancer patients with venous thromboembolism (VTE). Proc Am Soc Clin Oncol 2003;22:211.
45. Kakkar AK, Levine MN, Kadziola Z et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the Fragmin Advanced Malignancy outcome Study (FAMOUS). J Clin Oncol 2004;10:1944-1948.
46. Altinbas M, Coskun HS, Er O et al. A randomized clinical trial of combination chemotherapy with and without low-molecular weight heparin in small cell lung cancer. J Thromb Haemost 2004;2:1266-1271.
47. Woerner EM, Rowe RL. Trousseau's syndrome. Am Fam Physician 1988;38:195-201.
48. Agnelli G, Becattini C. Clinical and economic aspects of managing venous thromboembolism in the outpatient setting. Semin Haematol 2001;38(suppl 5):58-66.
49. Blattler W, Kreis N, Blattler IK. Practicability and quality of outpatient management of acute deep venous thrombosis. J Vasc Surg 2000;32:855-860.